Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial

OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy. ME...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Panaccione, Remo, Loftus, Edward V, Binion, David, McHugh, Kevin, Alam, Shamsul, Chen, Naijun, Guérette, Benoît, Mulani, Parvez, Chao, Jingdong
Formato: Artigo
Idioma:Inglês
Publicado: Pulsus Group Inc 2011
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186726/
https://ncbi.nlm.nih.gov/pubmed/21912766
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares